New Jersey is currently home to 1664 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Speech-derived Digital Biomarkers Study
NCT06994767
Recruiting
The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/20/2025
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease
Register for Updates
A Study of Hospital-at-Home for People Receiving Tarlatamab
NCT06957314
Recruiting
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey
Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma
Register for Updates
Generalization With AI Navigation Using StaRt
NCT06884943
Recruiting
Speech Sound Disorder (SSD) affects a significant portion of school-aged children, leading to social and emotional challenges that can persist into adolescence and adulthood. The number of productions necessary for a remediated speech sound to generalize to connected speech is challenging to achieve in practice, leading clinicians to call for accessible, reliable resources allowing children to continue therapy outside of direct clinical interactions. Artificial intelligence (AI) tools hold promi... Read More
Gender:
ALL
Ages:
Between 9 years and 17 years
Trial Updated:
05/20/2025
Locations: Montclair State University, Bloomfield, New Jersey
Conditions: Speech Sound Disorder
Register for Updates
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371
Recruiting
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
05/20/2025
Locations: Morristown Medical Center, Morristown, New Jersey
Conditions: Symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF)
Register for Updates
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683
Recruiting
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1) or Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/20/2025
Locations: Alkermes Investigational Site, Middletown, New Jersey
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Register for Updates
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772
Recruiting
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/20/2025
Locations: Sanmora Bespoke Clinical Research Solutions- Site Number : 8400015, East Orange, New Jersey
Conditions: Coeliac Disease, Celiac Disease
Register for Updates
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/20/2025
Locations: Alkermes Investigator Site, Middletown, New Jersey
Conditions: Narcolepsy Type 2
Register for Updates
Visual-acoustic Intervention With Service Delivery In-person and Via Telepractice Trial
NCT06517225
Recruiting
Children with speech sound disorder show diminished intelligibility in spoken communication and may thus be perceived as less capable than peers, with negative consequences for both socioemotional and socioeconomic outcomes. New technologies have the potential to transform interventions for speech sound disorder, but there is a lack of rigorous evidence to substantiate this promise. This research will meet a public health need by systematically evaluating the efficacy of visual-acoustic biofeedb... Read More
Gender:
FEMALE
Ages:
Between 9 years and 17 years
Trial Updated:
05/20/2025
Locations: Montclair State University, Bloomfield, New Jersey
Conditions: Speech Sound Disorder
Register for Updates
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779
Recruiting
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
05/20/2025
Locations: Research Site, New Brunswick, New Jersey
Conditions: Severe Asthma
Register for Updates
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810
Recruiting
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/20/2025
Locations: Research Site, New Brunswick, New Jersey
Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Register for Updates
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT06179888
Recruiting
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Memorial Sloan Kettering Monmouth, Middletown, New Jersey
Conditions: Multiple Myeloma
Register for Updates
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: The Valley Hospital, Inc., Paramus, New Jersey
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Register for Updates